Gilead, oNKo-innate Look To Natural Killer Cells For New Cancer Treatment [Yahoo! Finance News]
Gilead Sciences, Inc. (GILD)
Last gilead sciences, inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.gilead.com
Company Research
Source: Yahoo! Finance News
Gilead Sciences GILDCurrent cancer immunotherapy approaches primarily focus on T cell mediated anti-tumor immunity. Like T cells, NK cells are a class of lymphocytes white blood cells) that play a critical role in the immune system. Both NK cells and T cells each have the potential to attack cancer cells, but each have different mechanisms for tumor cell killing.According to Gilead, appropriately activated and targeted NK cells may represent a differentiated approach that would be potentially complementary and synergistic with T cell mediated strategies.Financial terms of the deal were not disclosed, but oNKo-innate will receive an upfront payment and potential additional payments based on achievement of certain milestones.Specifically, oNKo-innate will use genome-wide screening techniques and its proprietary technology platform to discover novel immune cell targets that enhance NK cell anti-tumor immunity and to create NK cell therapies.Overall GILD shows aModerate BuySee Gilead Scie
Show less
Read more
Impact Snapshot
Event Time:
GILD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GILD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GILD alerts
High impacting Gilead Sciences, Inc. news events
Weekly update
A roundup of the hottest topics
GILD
News
- Gilead Sciences (GILD) Registers a Bigger Fall Than the Market: Important Facts to Note [Yahoo! Finance]Yahoo! Finance
- Gilead Sciences Arcellx Deal Deepens Oncology Bet And Tests HIV Reliance [Yahoo! Finance]Yahoo! Finance
- Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of Columbia [Yahoo! Finance]Yahoo! Finance
- Gilead Foundation Awards $12 Million to Empower Community Health Workers and Expand HIV Prevention Initiatives Across 14 States and the District of ColumbiaBusiness Wire
- 3T Biosciences Appoints Rebeca Villarreal-Barragan, MBA, as Head of Clinical Operations [Yahoo! Finance]Yahoo! Finance
GILD
Earnings
- 2/10/26 - Beat
GILD
Sec Filings
- 3/2/26 - Form 4
- 3/2/26 - Form 4
- 3/2/26 - Form 4
- GILD's page on the SEC website